Immunology Investor Event
sanofi
Itepekimab: A potent IL-33 blocker with sub-nanomolar
affinity
Allergen
Smoke/pollutants
Pathogens (virus & bacteria)
IL-33
IL-33
IL-33
IL-33
IL-33
Neutrophil
NK Cell
Macrophage
Th1
Basophil
Mast cell
Eosinophil
Th2
Itepekimab is under investigation and not yet approved by any regulatory agency.
37 Immunology Investor Event
Binds to human IL-33 with high affinity (Kd = 42 PM)
Blocks the formation of the IL-33 / ST2 (IL-33
receptor) signaling complex and attenuates the
downstream inflammatory cascade including both
Type 2 and Type 1 immune responses
- Potential to be best and first-in-class IL-33 biologic to
treat former smokers with moderate to severe Type 2
and non-Type 2 COPD
- Potential for best-biologic efficacy, with unprecedented
exacerbation reduction in former smokersView entire presentation